Rocket Lab Corporation (RKLB) stock price rebounds after whipsaw week as Neutron update nears
29 January 2026
1 min read

Rocket Lab Corporation (RKLB) stock price rebounds after whipsaw week as Neutron update nears

New York, January 28, 2026, 21:36 (ET) — The market has closed.

  • After two volatile sessions, Rocket Lab shares ended the day up.
  • Attention turns to the company’s upcoming results and what it reveals about Neutron.
  • Any delay in Neutron’s schedule still poses a major risk to sentiment.

Rocket Lab shares rose 1.8% on Wednesday, finishing at $88.57. This move came after a volatile two-day stretch that kept the aerospace stock in the spotlight. The Nasdaq edged up roughly 0.2%. 1

Rocket Lab is set to release its fourth-quarter and full-year 2025 results on Feb. 26, right after U.S. markets close. The company will follow up with a conference call at 5 p.m. ET. 2

The big question now is when Neutron — Rocket Lab’s bigger rocket still in the works — will actually fly. According to a company statement, qualification testing of Neutron’s Stage 1 tank ended with a rupture during a hydrostatic pressure test, which is designed to stress the structure to its breaking point. Rocket Lab said it’s still evaluating how this might affect the launch timeline. 3

Rocket Lab kept up the hardware momentum. Its “Hungry Hippo” captive fairing landed at Wallops Island, Virginia, then moved to the Neutron assembly site. More pre-launch tests are set to take place nearby. 4

Electron, Rocket Lab’s smaller workhorse, is still pulling its weight. The company completed its first 2026 mission for Open Cosmos, successfully placing two satellites into a 1,050-kilometer circular orbit. CEO Sir Peter Beck called the launch “a great showcase” for dedicated Electron missions. 5

Neutron represents a bigger gamble for investors, aiming to push Rocket Lab into the heavy-lift tier currently ruled by SpaceX. Following the Stage 1 tank test failure, Space.com noted that a launch in the first quarter of 2026 now seems doubtful. 6

The company also sells spacecraft and components, doubling down on U.S. government demand. In December, the Space Development Agency struck deals with Rocket Lab and three major defense contractors to build a total of 72 missile-tracking satellites—18 apiece—valued at around $3.5 billion. Launches are set for 2029. 7

Traders will be watching closely in the next session to see if Rocket Lab can hold steady after this week’s wild swings, plunging sharply before rebounding just as quickly.

The real challenge lies ahead. Investors are set to demand clarity on launch schedules, cash requirements, and profit margins, along with a more precise update on how the Neutron tank rupture affected the timeline—if it affected it at all.

The downside risk is clear: any further test setbacks or extended delays with Neutron could shake confidence in a stock that’s been priced as if flawless execution is guaranteed.

Rocket Lab’s upcoming Feb. 26 earnings report and conference call will be the next big event. Expect most questions to focus on any changes to the Neutron launch schedule.

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Wells Fargo stock slips after Fed pause as bank shifts proxy voting in-house
Previous Story

Wells Fargo stock slips after Fed pause as bank shifts proxy voting in-house

Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching
Next Story

Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching

Go toTop